7096
StemCell Institute
ステムセル研究所
- Industry
- Services
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Notes
- Stock adjustmentsJan 1, 2023 Stock split 1 share → 2 shares
Key metrics
Revenue(thousand JPY)
Mar 2021
1,409,515
Mar 2022
1,781,943
Mar 2023
2,091,293
Mar 2024
2,481,193
Mar 2025
2,679,175
Operating profit(thousand JPY)
Mar 2021
86,879
Mar 2022
226,952
Mar 2023
297,560
Mar 2024
413,759
Mar 2025
418,509
Operating profit margin(%)
Mar 2021
6.16
Mar 2022
12.74
Mar 2023
14.23
Mar 2024
16.68
Mar 2025
15.62
Profit before tax(thousand JPY)
Mar 2021
91,446
Mar 2022
212,554
Mar 2023
278,957
Mar 2024
441,327
Mar 2025
565,712
Profit(thousand JPY)
Mar 2021
62,371
Mar 2022
133,726
Mar 2023
198,032
Mar 2024
310,981
Mar 2025
385,796
Total assets(thousand JPY)
Mar 2021
3,958,493
Mar 2022
5,215,602
Mar 2023
5,811,615
Mar 2024
6,543,075
Mar 2025
7,500,939
Cash and cash equivalents(thousand JPY)
Mar 2021
1,992,484
Mar 2022
3,510,318
Mar 2023
3,324,021
Mar 2024
2,845,540
Mar 2025
3,200,846
Cash flows from operating activities(thousand JPY)
Mar 2021
238,996
Mar 2022
469,290
Mar 2023
99,672
Mar 2024
334,625
Mar 2025
467,685
Cash flows from investing activities(thousand JPY)
Mar 2021
-520,262
Mar 2022
404,170
Mar 2023
-285,100
Mar 2024
-811,773
Mar 2025
-259,084
Cash flows from financing activities(thousand JPY)
Mar 2021
-
Mar 2022
644,373
Mar 2023
-869
Mar 2024
-1,333
Mar 2025
146,704
Return on equity(%)
Mar 2021
4.83
Mar 2022
7.81
Mar 2023
9
Mar 2024
12.46
Mar 2025
14.5
Equity ratio(%)
Mar 2021
33.4
Mar 2022
40.34
Mar 2023
39.55
Mar 2024
41.15
Mar 2025
35.03
Earnings per share(JPY per share)
Mar 2021
6.405
Mar 2022
13.205
Mar 2023
19.33
Mar 2024
30.35
Mar 2025
37.67
Net assets per share(JPY per share)
Mar 2021
135.83
Mar 2022
205.335
Mar 2023
224.33
Mar 2024
262.78
Mar 2025
258.35
Dividend per share(JPY per share)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
25
Payout ratio(%)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
66.37
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.